Evolving therapeutic strategies for retarding progression of diabetic nephropathy – an update for 2002

[1]  S. Tobe,et al.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure? , 2001, Current hypertension reports.

[2]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[3]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[4]  F Vinicor,et al.  The continuing epidemics of obesity and diabetes in the United States. , 2001, JAMA.

[5]  H. Parving,et al.  Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. , 2000, Diabetes care.

[6]  G. Bakris,et al.  Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management , 2000, Journal of Human Hypertension.

[7]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[9]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[10]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[11]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[12]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[13]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[14]  B. Brenner,et al.  Hemodynamic theory of progressive renal disease: a 10-year update in brief review. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  B. Brenner,et al.  Reversing glomerular hypertension stabilizes established glomerular injury. , 1987, Kidney international.

[16]  M. Epstein.  Calcium antagonists and the kidney. , 1987, Journal of cardiovascular pharmacology.

[17]  B. Brenner,et al.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. , 1986, The Journal of clinical investigation.

[18]  C. Bulpitt,et al.  Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. , 1999, The New England journal of medicine.

[19]  C. Nzerue.  Calcium antagonists and renal disease. , 1999, Kidney international.

[20]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[21]  P. Fiévet,et al.  [Calcium antagonists and the kidney]. , 1989, Annales de medecine interne.